Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 28, 2023

BUY
$1.19 - $2.09 $23,400 - $41,097
19,664 Added 139.25%
33,785 $43,000
Q4 2022

Feb 02, 2023

SELL
$1.67 - $2.35 $15,118 - $21,274
-9,053 Reduced 39.07%
14,121 $26,000
Q3 2022

Oct 31, 2022

BUY
$1.81 - $2.76 $15,600 - $23,788
8,619 Added 59.22%
23,174 $45,000
Q2 2022

Jul 29, 2022

BUY
$1.34 - $5.34 $19,503 - $77,723
14,555 New
14,555 $30,000
Q1 2022

Apr 29, 2022

SELL
$4.58 - $6.8 $63,987 - $95,002
-13,971 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$5.23 - $7.18 $99,401 - $136,463
-19,006 Reduced 57.63%
13,971 $90,000
Q3 2021

Nov 01, 2021

BUY
$5.94 - $8.75 $195,883 - $288,548
32,977 New
32,977 $204,000
Q1 2021

May 13, 2021

SELL
$4.76 - $11.25 $48,190 - $113,895
-10,124 Closed
0 $0
Q4 2020

Feb 04, 2021

BUY
$2.43 - $5.42 $24,601 - $54,872
10,124 New
10,124 $49,000
Q3 2020

Nov 09, 2020

SELL
$2.3 - $3.72 $61,612 - $99,651
-26,788 Closed
0 $0
Q2 2020

Jul 20, 2020

BUY
$1.33 - $3.63 $13,006 - $35,497
9,779 Added 57.49%
26,788 $83,000
Q1 2020

Apr 30, 2020

BUY
$1.27 - $2.33 $21,601 - $39,630
17,009 New
17,009 $24,000
Q2 2019

Jul 29, 2019

SELL
$2.05 - $4.32 $42,209 - $88,948
-20,590 Closed
0 $0
Q1 2019

Apr 29, 2019

BUY
$1.79 - $3.12 $18,914 - $32,969
10,567 Added 105.43%
20,590 $43,000
Q4 2018

Feb 01, 2019

BUY
$2.24 - $3.9 $22,451 - $39,089
10,023 New
10,023 $26,000
Q3 2018

Nov 06, 2018

SELL
$3.58 - $4.9 $37,049 - $50,710
-10,349 Closed
0 $0
Q2 2018

Aug 07, 2018

SELL
$4.43 - $5.14 $20,462 - $23,741
-4,619 Reduced 30.86%
10,349 $49,000
Q1 2018

May 03, 2018

SELL
$4.65 - $5.9 $26,779 - $33,978
-5,759 Reduced 27.79%
14,968 $78,000
Q4 2017

Jan 24, 2018

BUY
$4.32 - $5.52 $89,540 - $114,413
20,727
20,727 $96,000

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $85M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.